AbbVie Inc.
AbbVie Inc. demonstrates strong business quality and financial strength, coupled with decent profitability and capital allocation. However, recent growth metrics show some decline, and the valuation appears stretched.
Business Performance (CAGR)
Valuation Snapshot
Financial Health
Profitability Metrics
Cash Flow Intelligence
Intrinsic Value
PremiumEstimated Intrinsic Value & DCF Fair Value are available with Premium plans.
AI Business Verdict
AbbVie Inc. exhibits strong fundamental business qualities and robust free cash flow generation. However, significant concerns around negative shareholder equity, poor profit growth, and a high valuation present substantial risks. The intrinsic value assessment suggests the company is considerably overvalued at its current price. While the business has operational strengths, its financial structure and profit dynamics require significant improvement for sustainable long-term value creation.
- Consistent revenue growth (10.14% CAGR).
- Strong free cash flow generation (8.38% FCF CAGR).
- High operating cash flow relative to net profit (450.31% OCF to PAT).
- Solid business quality (score 64) and financial strength (score 63).
Balance Sheet
AbbVie Inc. has an adequate but tight balance sheet — leverage and liquidity warrant monitoring.
Capacity to fund growth, withstand downturns and return capital.
- AbbVie Inc.
- has an adequate but tight balance sheet — leverage and liquidity warrant monitoring.
- Very low leverage with net cash balance
- Tight short-term liquidity cushion
- Long working capital cycle
- Large 'other assets' bucket — investigate composition
- Slow book value compounding